Searched for
CEFEPIME AND ZIDEBACTAM
Pharma in her DNA, Wockhardt scion ready for deep dive in the USZahabiya Khorakiwala is leading Wockhardt's US business and the launch of its new antibiotic, Zaynich. This drug targets resistant bacteria...- Wockhardt shares pause massive 36% rally in 5 sessions; slip 7%. What’s behind the selloff?Wockhardt shares dropped after a recent surge, as investors took profits. This followed the US FDA approval of ZAYNICH, an antibiotic for u...
- Wockhardt shares rocket 19% after FDA approval for antibiotic targeting drug-resistant infections. Check detailsWockhardt's shares surged 19% after the U.S. FDA approved ZAYNICH, a novel intravenous antibiotic for complicated urinary tract infections....
- FDA approval puts Wockhardt’s Zaynich in $9 billion antibiotics marketWockhardt's new antibiotic, Zaynich, has received US FDA approval. This drug uses a novel mechanism to fight drug-resistant bacteria. It ta...
- Wockhardt secures US FDA approval for antibiotic ZaynichWockhardt's novel antibiotic, Zaynich (cefepime and zidebactam), has received US FDA approval for complicated urinary tract infections. Thi...
- Wockhardt shares jump 8%, extend rally after CDSCO nod for Zaynich antibioticWockhardt shares surged after the company received CDSCO approval for its breakthrough antibiotic Zaynich in India. Strong Phase 3 trial re...
- Wockhardt gets CDSCO nod for Zaynich antibioticWockhardt Ltd has secured approval from the CDSCO for its new antibiotic, Zaynich. This drug is developed in India and will be used to trea...
- USFDA accepts Wockhardt’s NDA for breakthrough antibiotic ZaynichThis is the first time ever that an NDA from a new chemical entity (NCE) from an Indian pharma company has been filed and accepted by the U...
- Indian pharma Wockhardt seeks US approval for new drug to treat UTIsWockhardt has submitted a New Drug Application to the USFDA for its novel antibacterial agent, Zidebactam-Cefepime injection. This drug tar...
- Wockhardt exits US generics biz to focus on drug discoveryWockhardt is set to exit its loss-making US generics business to prioritize innovation, focusing on new antibiotic drug discovery and its b...
- Wockhardt activates Zaynich push, eyes global licensing dealsWockhardt is advancing Zaynich, a novel antibiotic combination, targeting drug-resistant infections, with plans for regulatory submissions ...
- Wockhardt shares skyrocket 18% to fresh 52-week high. Here’s why?Shares of Wockhardt surged 18% in early trading to reach a new 52-week high of Rs 811.50 on NSE. The sharp increase followed the company's ...
- USFDA okays abridged clinical trial for antibiotic: WockhardtThe decision was based on the evaluation by USFDA of its preclinical and clinical data of phase I establishing safety and clinical scope of...
Load More
